Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis.
Nabiximols oromucosal spray is an investigational complex botanical mixture formulated from extracts of the cannabis sativa plant. The investigational treatment contains the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), along with other cannabinoid and noncannabinoid components.
To read the full article published in the Medical Professionals Reference, click here: https://www.empr.com/home/news/drugs-in-the-pipeline/cannabis-derived-oromucosal-spray-misses-in-ms-spasticity-trial/
For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.
Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.